Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Soluble urokinase-type plasminogen activator receptor (suPAR) - a possible biomarker for bacteremia in sepsis
    Georgescu, Anca-Meda
    Szederjesi, Janos
    Voidazan, Septimiu
    Dobreanu, Minodora
    Copotoiu, Sanda Maria
    Hutanu, Adina
    Azamfirei, Leonard
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2015, 23 (01): : 59 - 73
  • [22] Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis
    Savva, Athina
    Raftogiannis, Maria
    Baziaka, Fotini
    Routsi, Christina
    Antonopoulou, Anastasia
    Koutoukas, Pantelis
    Tsaganos, Thomas
    Kotanidou, Anastasia
    Apostolidou, Efterpi
    Giamarellos-Bourboulis, Evangelos J.
    Dimopoulos, George
    JOURNAL OF INFECTION, 2011, 63 (05) : 344 - 350
  • [23] Relationship of Circulating Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels to Disease Control in Asthma and Asthmatic Pregnancy
    Ivancso, Istvan
    Toldi, Gergely
    Bohacs, Aniko
    Eszes, Noemi
    Mueller, Veronika
    Rigo, Janos, Jr.
    Vasarhelyi, Barna
    Losonczy, Gyoergy
    Tamasi, Lilla
    PLOS ONE, 2013, 8 (04):
  • [24] Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
    Hoybye, Charlotte
    Faseh, Laia
    Himonakos, Christos
    Pielak, Tomasz
    Eugen-Olsen, Jesper
    ENDOCRINE CONNECTIONS, 2019, 8 (06): : 772 - 779
  • [25] The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia
    Wrotek, A.
    Jackowska, T.
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2015, 209 : 120 - 123
  • [26] Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
    Oezdirik, Burcin
    Stueven, Anna
    Knorr, Jana
    Geisler, Lukas
    Mohr, Raphael
    Demir, Muenevver
    Hellberg, Teresa
    Loosen, Sven H.
    Benz, Fabian
    Wiedenmann, Bertram
    Tacke, Frank
    Wree, Alexander
    Jann, Henning
    Roderburg, Christoph
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [27] Effects of Acute Exercise and Allopurinol Administration on Soluble Urokinase Plasminogen Activator Receptor (suPAR)
    Sanchis-Gomar, Fabian
    Bonaguri, Chiara
    Pareja-Galeano, Helios
    Carmen Gomez-Cabrera, Mari
    Candel, Jorge
    Vina, Jose
    Lippi, Giuseppe
    CLINICAL LABORATORY, 2013, 59 (1-2) : 207 - 210
  • [28] Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients
    Lippi, Giuseppe
    Henry, Brandon M.
    Favaloro, Emmanuel J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (11) : E413 - E415
  • [29] Serum Soluble Urokinase Plasminogen Activator Receptor Levels in Resistant Hypertension
    Bayrakci, Nergiz
    Ozkan, Gulsum
    Kara, Sonat Pinar
    Yilmaz, Ahsen
    Celikkol, Aliye
    TURKISH JOURNAL OF NEPHROLOGY, 2024, 33 (02): : 173 - 178
  • [30] Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) as a possible biomarker for lung cancer and/or COPD
    Loukeri, Angeliki
    Spithakis, Panagiotis-Dimitrios
    Moschos, Charalampos
    Loukeri, Pinelopi
    Bartzeliotou, Anastasia
    Tzagkaraki, Aikaterini
    Stratos, Eustratios
    Veldekis, Dimitrios
    Kampolis, Christos F.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48